Having trouble accessing articles? Reset your cache.

Rolofylline: Additional Phase III data

Additional data from the double-blind, international Phase III PROTECT trial in 2,033 patients showed that 30 mg/day IV rolofylline for up to

Read the full 229 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE